New findings from M. Robin and co-authors describe advances in leukemia
2008 JAN 14 -- According to a study from Paris, France, "After allogencic hematopoietic stem cell transplantation (HSCT), early infections represent a major cause of morbidity and mortality but little information has been previously reported on late infections. Late infection incidence and risk factors were retrospectively determined in 196 long-term survivors after HLA matched related HSCT." "Patients transplanted for aplastic anemia, chronic myelogenous leukemia (CML), and acute myclogenous leukemia (AML) were included. Median follow-up was 8 years. Thirty patients died beyond the first year, causes of death were relapse (n = 10) and infections (n = 19, associated with graft-versus-host disease [GVHD] in 16 patients). Late severe bacterial (LSB) and fungal infections occurred in 30 and 8 patients, yielding to an 8-year cumulative incidence of 15 (95%Cl: 10-20) and 4% (95%Cl: 1-6), respectively. The majority of viral infections were hepatitis C (HCV) and VZV (8-year cumulative incidence: 10 (95%Cl: 5-14) and 27% (95%Cl: 20-34), respectively. Three risk factors for LSB have been identified in multiple Cox analysis: CNIV status (positive recipient and negative donor) (hazard ratio [HR]: 2.5, 95%Cl: 1.1-5.9, P =.033), irradiation-based conditioning regimen (HR: 3.1, 95%Cl: 1.2-7.8, P =.016), and extensive chronic GVHD (cGVHD; HR: 2.9, 95%Cl: 1.3-6.9, P =.013). Extensive cGVHD was the only risk factor for non-HCV viral infections in patients transplanted for AML or CML (HR: 2.7,95%Cl: 1.4-5.1, P =.002)," wrote M. Robin and colleagues. The researchers concluded: "After HSCT, patients remain at high risk of infections even late after transplantation, in particular, with the above risk factors, and required a prolonged follow-up." Robin and colleagues published the results of their research in Biology of Blood and Marrow Transplantation (Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor. Biology of Blood and Marrow Transplantation, 2007;13(11):1304-1312). For additional information, contact G. Socie, Greffe Hopital St. Louis, Service Hematology, AP HP, 1 Avenue Claude Vellefaux, F-75010 Paris, France. The publisher of the journal Biology of Blood and Marrow Transplantation can be contacted at: Elsevier Science Inc., 360 Park Avenue South, New York, NY 10010-1710, USA. Keywords: France, Paris, Aplastic Anemia, Bone Marrow Transplantation, Cell Transplantation, Chronic Myelogenous Leukemia, Graft-Versus-Host Disease, Hematology, Hematopoietic, Oncology, Stem Cell Research, Surgery. This article was prepared by Stem Cell Week editors from staff and other reports. Copyright 2008, Stem Cell Week via NewsRx.com.
|
